PDF(Pubmed)
Abstract：
Esophageal cancer ranks among the ten most common cancers worldwide. Despite the adoption of neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by surgery as the standard treatment approach in recent years, the local recurrence rate remains high. In this study, we employed RNA-seq to investigate distinctive gene expression profiles in esophageal squamous cell carcinoma (ESCC) with or without recurrence following a standard treatment course. Our findings indicate that recurrent ESCC exhibits heightened keratinizing and epidermis development activity compared to non-recurrent ESCC. We identified TP63 as a potential candidate for distinguishing clinical outcomes. Furthermore, immunohistochemistry confirmed the trend of TP63 overexpression in ESCC recurrence. Patients with elevated TP63 expression had poorer overall survival and lower 3-year recurrence-free survival. This study underscores the potential of TP63 as a biomarker for detecting cancer recurrence and suggests its role in guiding future treatment options.
摘要：
食管癌是全球十大最常见的癌症之一。尽管近年来采用了新辅助同步放化疗（nCCRT），然后手术作为标准治疗方法，局部复发率仍然很高。在这项研究中,我们使用RNA-seq研究标准疗程后有或无复发的食管鳞状细胞癌(ESCC)的独特基因表达谱.我们的发现表明，与非复发性ESCC相比，复发性ESCC表现出增强的角质化和表皮发育活性。我们确定TP63是区分临床结果的潜在候选者。此外，免疫组织化学证实了TP63过表达在ESCC复发中的趋势。TP63表达升高的患者总生存率较差，3年无复发生存率较低。这项研究强调了TP63作为检测癌症复发的生物标志物的潜力，并表明其在指导未来治疗方案中的作用。
